📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
EMA Grants Accelerated Assessment to Wockhardt's WCK 5222 Antibiotic
The European Medicines Agency (EMA) has granted Accelerated Assessment to Wockhardt's novel antibiotic WCK 5222 (Zaynich®), which targets multi-drug resistant Gram-negative infections. This designation is reserved for drugs addressing unmet medical needs and will significantly speed up the review process for pan-European marketing authorization. WCK 5222 has already completed global Phase III trials and has pending applications with the USFDA and Indian regulators. This marks the first time an Indian-discovered New Chemical Entity (NCE) is being submitted for such authorization in Europe.
Key Highlights
EMA grants Accelerated Assessment for WCK 5222 (Zidebactam 1g + Cefepime 2g) to treat life-threatening MDR/XDR infections.
WCK 5222 is the first Indian-discovered NCE submitted for pan-European marketing authorization.
Global Phase III clinical trials are complete, with NDA already filed and accepted by the USFDA.
Wockhardt's pipeline includes 6 antibiotics with USFDA QIDP designation, with 77% of revenue coming from international markets.
👀 What to Watch
Investors should view this as a major de-risking event for Wockhardt's R&D pipeline, potentially leading to faster commercialization in the European market. Monitor USFDA and Indian regulatory approvals as subsequent catalysts for the stock.
Wockhardt Incorporates 3 New Step-Down Subsidiaries in Switzerland and USA
Wockhardt Limited has incorporated three new wholly-owned step-down subsidiaries in Switzerland and the United States through its subsidiary Wockhardt Bio AG. The new entities include Wockhardt Swiss AG, Wockhardt Suisse USA Holding Corporation, and Wockhardt Suisse USA LLC, with initial capital investments of CHF 50,000 and USD 50,000 respectively. These subsidiaries are strategically designed to channelize the company's antibiotic and other pharmaceutical products across European and American markets. While the entities have not yet commenced operations, they represent a structural move to enhance global distribution capabilities.
Key Highlights
Incorporated Wockhardt Swiss AG in Switzerland with a subscribed capital of CHF 50,000.
Established two US-based entities with a combined initial capital subscription of USD 100,000.
Entities are 100% step-down subsidiaries intended to facilitate the distribution of antibiotic products.
Wockhardt Swiss AG was incorporated on December 1, 2025, while the US entities followed on December 11, 2025.
👀 What to Watch
Investors should view this as a routine corporate restructuring to support international sales; monitor future filings for updates on when these entities begin generating revenue.
Wockhardt Shareholders Approve Om Prakash Bhatt as Independent Director with 99.99% Votes
Wockhardt Limited shareholders have overwhelmingly approved the appointment of Mr. Om Prakash Bhatt as a Non-Executive Independent Director for a five-year term ending November 2030. The special resolution, which also permits him to continue his directorship beyond the age of 75, received 99.99% support from voting members. Out of approximately 10.82 crore valid votes polled, 10.81 crore were in favor, with near-unanimous support from both promoters and public institutions. This appointment brings significant leadership experience to the board, as Mr. Bhatt is a former Chairman of the State Bank of India.
Key Highlights
Special resolution passed for Om Prakash Bhatt's appointment as Independent Director for a 5-year term.
The resolution received 99.9921% votes in favor, reflecting strong shareholder confidence.
100% of voting public institutions (2.46 crore shares) and promoters (7.97 crore shares) supported the move.
Shareholders specifically approved his continuation in office notwithstanding his attaining the age of 75 during the term.
👀 What to Watch
Investors should view this as a positive governance development, as the inclusion of a high-caliber professional like Mr. Bhatt strengthens the board's oversight. No immediate portfolio changes are required based on this administrative update.
Wockhardt's Zaynich NDA Accepted by US FDA - A First for Indian Pharma
Wockhardt Ltd. announced that the US FDA has accepted the New Drug Application (NDA) for its antibiotic Zaynich, marking the first time an Indian pharmaceutical company has achieved this milestone for a New Chemical Entity (NCE). The NDA was filed on September 30, 2025. Zaynich has received Fast Track designation from the FDA, potentially expediting the review process. This acceptance highlights Wockhardt's innovation and could lead to significant revenue opportunities if the drug is approved.
Key Highlights
US FDA accepts Wockhardt’s New Drug Application for Zaynich
First-ever NDA Acceptance for an Indian Pharmaceutical Company
NDA was originally filed on September 30, 2025
Zaynich has been granted Fast Track designation by the US FDA
Wockhardt initiated Zaynich development program in 2011
👀 What to Watch
Investors should monitor the FDA's review process for Zaynich, as approval could significantly impact Wockhardt's future revenue and market position. Positive news regarding the review process may present a buying opportunity.
